臨床神経学

第49回日本神経学会総会

<シンポジウム10-4>ミトコンドリア病治療の現況と将来
ミトコンドリア病の新しい治療戦略

後藤 雄一

国立精神・神経センター神経研究所〔〒187-8502 小平市小川東町4-1-1〕

Mitochondrial diseases have a peculiar character of variability that expands from DNA, cell and tissue/organ levels to family/society level. These kinds of variability seem an obstacle to prevent us from developing new and effective therapies for this disease. Selective delivery system to mitochondria can make us get a promising new strategy to treat and prevent the disease. MITO-Porter may be a powerful system in which we can introduce a various kind of materials including DNA, RNA, enzyme and drugs to mitochondria in vivo.
Full Text of this Article in Japanese PDF (394K)

(臨床神経, 48:1016−1017, 2008)
key words:ミトコンドリア病, エネルギー代謝, 活性酸素, MITO-Porter

(受付日:2008年5月17日)